Equities

ImmuPharma PLC

IMM:LSE

ImmuPharma PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)2.05
  • Today's Change0.01 / 0.49%
  • Shares traded516.61k
  • 1 Year change-33.76%
  • Beta2.4849
Data delayed at least 20 minutes, as of May 03 2024 15:11 BST.
More ▼

Profile data is unavailable for this security.

About the company

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company is focused on developing peptide bio-drugs in specialty therapeutic areas. Its portfolio includes peptide therapeutics for autoimmune diseases and anti-infectives. Its lead program, P140 (Lupuzor), is an autophagy immunomodulator for the treatment of lupus. Its pipeline is focused on two therapeutic areas: autoimmunity/inflammation and anti-infectives. Its pipeline products in autoimmunity and inflammation therapeutic area includes Lupuzor and P140 for CIDP. Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB, a peptide-based drug that offers a potential improvement on the limiting side effects and poor administration regime of Amphotericin-B (AMB) formulations. BioCin, a peptide-based drug based on an existing antibacterial used in high medical need and in many cases as the last line of defense.

  • Revenue in GBP (TTM)69.96k
  • Net income in GBP-2.99m
  • Incorporated2000
  • Employees13.00
  • Location
    ImmuPharma PLCOne Bartholomew CloseLONDON EC1A 7BLUnited KingdomGBR
  • Phone+44 20 7152 4080Fax+44 20 7152 4001
  • Websitehttps://www.immupharma.co.uk/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
ValiRx Plc0.00-2.41m4.30m8.004.30m8.00
BSF Enterprise PLC12.94k-1.50m4.91m4.004.91m4.00
Cizzle Biotechnology Holdings PLC0.00-953.00k6.54m67.006.54m67.00
Genflow Biosciences PLC0.00-1.18m7.17m0.007.17m0.00
ImmuPharma PLC69.96k-2.99m8.50m13.008.50m13.00
Cambridge Nutritional Sciences PLC9.05m-3.21m9.40m91.009.40m91.00
Bivictrix Therapeutics PLC0.00-2.33m9.49m10.009.49m10.00
Proteome Sciences plc5.03m-2.44m10.36m35.0010.36m35.00
Chill Brands Group PLC146.62k-3.64m11.14m2.0011.14m2.00
Kanabo Group PLC813.00k-4.66m11.70m20.0011.70m20.00
Abingdon Health PLC5.34m-2.24m11.87m82.0011.87m82.00
Synairgen plc0.00-9.99m12.32m30.0012.32m30.00
Data as of May 03 2024. Currency figures normalised to ImmuPharma PLC's reporting currency: UK Pound GBX

Institutional shareholders

33.84%Per cent of shares held by top holders
HolderShares% Held
KW Investment Management Ltd.as of 01 Mar 202471.29m17.12%
Hargreaves Lansdown Asset Management Ltd.as of 01 Mar 202420.40m4.90%
Chelverton Asset Management Ltd.as of 30 Jun 202315.00m3.60%
HSBC Global Asset Management (UK) Ltd.as of 01 Mar 202411.10m2.67%
IG Markets Ltd.as of 01 Mar 202410.54m2.53%
Bank J. Safra Sarasin AG (Investment Management)as of 01 Mar 20243.26m0.78%
HSBC Bank Plc (Market-Maker)as of 01 Mar 20242.56m0.62%
Jarvis Investment Management Ltd.as of 01 Mar 20242.44m0.59%
Close Asset Management Ltd.as of 01 Mar 20242.24m0.54%
Aviva Investors Global Services Ltd.as of 20 Apr 20182.09m0.50%
More ▼
Data from 30 Sep 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.